PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsLenograstim
Lenograstim
Lenograstim is a protein pharmaceutical. It is currently being investigated in clinical studies. It is known to target granulocyte colony-stimulating factor receptor and macrophage colony-stimulating factor 1 receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
— L03: Immunostimulants
— L03A: Immunostimulants
— L03AA: Colony stimulating factors
— L03AA10: Lenograstim
HCPCS
No data
Clinical
Clinical Trials
1694 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
LymphomaD008223—C85.980207441227334
LeukemiaD007938—C959820251927332
Myeloid leukemia acuteD015470—C92.06412232314205
Multiple myelomaD009101—C90.04110723418175
Non-hodgkin lymphomaD008228—C85.94510519413164
Myelodysplastic syndromesD009190—D46509518313151
Breast neoplasmsD001943EFO_0003869C50337039148147
Myeloid leukemiaD007951—C9241852419139
Precursor cell lymphoblastic leukemia-lymphomaD054198—C91.0398216911138
NeoplasmsD009369—C80634415411122
Show 62 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hodgkin diseaseD006689—C81215913—486
Large b-cell lymphoma diffuseD016403—C83.329389—670
SarcomaD012509——204111—368
B-cell chronic lymphocytic leukemiaD015451—C91.124364—763
Myeloproliferative disordersD009196—D47.123314—759
Mantle-cell lymphomaD020522—C83.122323—553
Bcr-abl positive chronic myelogenous leukemiaD015464EFO_0000340—14364—351
Central nervous system neoplasmsD016543——17305—250
Follicular lymphomaD008224—C8221245—547
B-cell lymphomaD016393——14214—536
Show 133 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Biphenotypic leukemia acuteD015456—C95.01214———19
Pancreatic neoplasmsD010190EFO_0003860C2578——214
Hiv infectionsD015658EFO_0000764B2037——414
Fanconi anemiaD005199Orphanet_84D61.03610——113
Blast crisisD001752——66——112
Fallopian tube neoplasmsD005185——64——110
T-cell lymphomaD016399——18——110
T-cell lymphoma peripheralD016411———9——110
Colorectal neoplasmsD015179——46——19
Primitive neuroectodermal tumors peripheralD018241——55——19
Show 194 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hairy cell leukemiaD007943—C91.43———36
PinealomaD010871——3————3
Coronary artery diseaseD003324—I25.11———23
Rheumatoid arthritisD001172EFO_0000685M06.92———13
ArthritisD001168EFO_0005856M05-M142———13
Aids-related complexD000386EFO_0007137B201———23
Neoplasms by histologic typeD009370——2————2
MeningiomaD008579EFO_0003098D32.92————2
VasculitisD014657EFO_0006803M311———12
Juvenile arthritisD001171EFO_1002007M081———12
Show 40 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Arterial occlusive diseasesD001157EFO_0009085—————22
Hemophagocytic lymphohistiocytosisD051359—D76.1————22
Thrombocytopenic purpura idiopathicD016553EFO_0007160D69.3————22
Diabetic neuropathiesD003929EFO_1000783—————22
Brain injuriesD001930—S06.9————22
Intermittent claudicationD007383EFO_0003876I73.9————11
Abnormal karyotypeD059786——————11
Lupus nephritisD008181EFO_0005761—————11
NephritisD009393—N05————11
Chediak-higashi syndromeD002609Orphanet_167D72.0————11
Show 30 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameLenograstim
INNlenograstim
Description
Lenograstim is a recombinant granulocyte colony-stimulating factor which functions as an immunostimulator. It is developed by Chugai Pharmaceuticals under the brand name Granocyte.
Classification
Protein
Drug classcolony-stimulating factors: granulocyte colony-stimulating factors (G-CSF)
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID—
RxCUI—
ChEMBL IDCHEMBL2109128
ChEBI ID—
PubChem CID—
DrugBank—
UNII ID6WS4C399GB (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
CSF3R
CSF3R
Organism
Homo sapiens
Gene name
CSF3R
Gene synonyms
GCSFR
NCBI Gene ID
Protein name
granulocyte colony-stimulating factor receptor
Protein synonyms
CD114, CD114 antigen, colony stimulating factor 3 receptor (granulocyte), G-CSF receptor, G-CSF-R
Uniprot ID
Mouse ortholog
Csf3r (12986)
granulocyte colony-stimulating factor receptor (P40223)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 1,017 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
1,256 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use